medRxivGenetic & Genomic MedicinePreprint
Resolving inflammatory bowel disease risk variants to genes and cell types
Laura FachaliD, Rui ZhangiD, Kyle GettleriD, Talin HarituniansiD, Isabelle CleyneniD, Christine R. StevensiD, Qian ZhangiD, Christopher TastadiD, Catalina Medici, Ron DoiD, Maria Teresa AbreuiD, Jean–Paul AchkariD, Tariq AhmadiD, Klaartje Bel KokiD, Charles BernsteiniD, Johanne BrooksiD, Luis BujandaiD, Jeffrey R. Butterworth, Katie Clark, Fraser J.R. CummingsiD, Mauro D’AmatoiD, Joanne Del Buono, Richard H. DuerriD, David EllinghausiD, Stephen Foley, , Judy H. ChoiD
Abstract
Inflammatory bowel diseases (IBD), principally Crohns disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77-80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
- organism: human
- assay: GWAS summary statistics
- research focus: fine-mapping
- research focus: gene regulatory network inference
- research focus: benchmarking
- approach: statistical model
- approach: Bayesian inference
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Association mapping of inflammatory bowel disease loci to single variant resolution
Hailiang Huang, Ming Fang, … International IBD Genetics Consortiu·bioRxiv·Oct 20, 2015
- Cell-type-resolved genetic regulatory variation shapes inflammatory bowel disease risk
Tobi Alegbe, Bradley T. Harris, … Carl A. Anderson·medRxiv·Jun 24, 2025
- Multi-ancestry genome-wide and transcriptome-wide association analyses identify new risk loci and genes for inflammatory bowel disease
Xingyi Guo, Linshuoshuo Lyu, … Ken S. Lau·medRxiv·Sep 23, 2025
- Exome sequencing and genotyping identify a rare variant in NLRP7 gene associated with ulcerative colitis.
Alexandros Onoufriadis, Kristina L. Stone, … Natalie J. Prescott·Journal of Crohn s and ColitisPeer-reviewed·Dec 1, 2017
- eQTL in diseased colon tissue identifies novel target genes associated with IBD
Nina C. Nishiyama, Sophie Silverstein, … Terrence S. Furey·bioRxiv·Oct 14, 2024
- Identifying novel high-impact rare disease-causing mutations, genes and pathways in exomes of Ashkenazi Jewish inflammatory bowel disease patients
Yiming Wu, Kyle Gettler, … Yuval Itan·medRxiv·Jul 1, 2020